In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record